Author(s)
Fens T1, van Boven JFM2, Mihajlović J3, van Puijenbroek EP4, Postma M5
1University of Groningen, Department of PharmacoTherapy, Epidemiology & -Economics (PTE2) and Department of Health Sciences, UMCG, Groningen, Netherlands, 2University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy & Pharmacology, Groningen, Netherlands, 3University of Groningen, University Medical Center Groningen, Department of Health Sciences; Mihajlović Health Analytics & University of Novi Sad, Medical Faculty, Novi Sad, Serbia, 4University of Groningen, Department of PharmacoTherapy, Epidemiology & -Economics (PTE2), Groningen Research Institute of Pharmacy and Netherlands Pharmacovigilance Centre Lareb, Groningen, Netherlands, 5University of Groningen, University Medical Center Groningen, Department of Health Sciences & SHARE; Faculty of Economics & Business, Department of Economics, Econometrics & Finance, Groningen, Netherlands
Recent publications studying the public's view on the social value of vaccines showed that the public assigns more weight to the vaccine’s Adverse Events (AEs), than to its efficacy in preventing the infection. Therefore, inclusion of AEs into economic analyses, which are common components in public funding decisions for vaccines, is important and urgent to address. Notably, of all previous economic evaluations of influenza vaccination only 16% included AEs. This urged us to use the collected data and act towards improved utilization of safety data within the economic evaluation on seasonal influenza vaccines, and potentially expand this to a different therapeutic area. To address this need, we created an online interactive platform, Safety-Research Database for and from Economic Evaluations (SRD-EE) (available at srdee.com). SRD-EE allows stakeholders to: (1) find AE-related published data in economic evaluations, and (2) contribute/add AE-related data from novel economic evaluations. The data in SRD-EE is organized per therapeutic area and includes AE costs (unit costs, sources, direct or indirect costs) as well as other relevant AE-related information (QALYs loss due to AE, probability/frequency of AE occurrence, duration in days having the AE or days of productivity losses due to AEs). The SRD-EE platform facilitates the access and use of AE-related data, and potentially increases its future inclusion within economic evaluations. The tool itself targets researchers, regulators, decision makers and payers. It represents a sustainable, standardized yet flexible concept to capture AE-related data from different disciplines/therapeutic areas, and could therefore contribute to more representative allocation of public health resources.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSA429
Disease
Multiple Diseases
